Elevated levels of serum matrix metalloproteinase‐9 (MMP‐9) during the acute phase of ischemic stroke are indicative of an augmented risk for mortality and significant disability (Maestrini et al., 2020; Zhong et al., 2017). This evidence concerns the gene MMP9 and ischemic stroke.